GRAIL, Inc.(GRAL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

GRAL GRAIL, Inc.

Trading 04-06 14:43:43 EDT

51.71

-3.28

-5.96%

High55.12	Low51.27	Vol508.39K
Open54.61	D1 Closing54.99	Amplitude7.00%
Mkt Cap2.12B	Tradable Cap1.77B	Total Shares41.02M
T/O26.70M	T/O Rate1.49%	Tradable Shares34.19M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"GRAL","market":"US","secType":"STK","nameCN":"GRAIL, Inc.","latestPrice":51.71,"timestamp":1775501020838,"preClose":54.99,"halted":0,"volume":508388,"delay":0,"changeRate":-0.05964720858337882,"floatShares":34193700,"shares":41020255,"eps":-11.110457,"marketStatus":"Trading","change":-3.28,"latestTime":"04-06 14:43:43 EDT","open":54.61,"high":55.12,"low":51.27,"amount":26696952.099436,"amplitude":0.070013,"askPrice":51.77,"askSize":4,"bidPrice":51.66,"bidSize":305,"shortable":3,"etf":0,"ttmEps":-11.110457,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1775505600000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":54.99,"preHourTrading":{"tag":"盘前","latestPrice":54.77,"preClose":54.99,"latestTime":"09:20 EDT","volume":319,"amount":17518.514387,"timestamp":1775481603898,"change":-0.22,"changeRate":-0.004001,"amplitude":0.007638},"postHourTrading":{"tag":"盘后","latestPrice":55.15,"preClose":54.99,"latestTime":"19:39 EDT","volume":12204,"amount":671028.356,"timestamp":1775173175195,"change":0.16,"changeRate":0.00291,"amplitude":0.00291},"volumeRatio":0.753867,"impliedVol":0.9234,"impliedVolPercentile":0.368},"requestUrl":"/m/hq/s/GRAL/wiki","defaultTab":"wiki","newsList":[{"id":"2624436565","title":"BRIEF-Superpower Announces Strategic Partnership With GRAIL For Multi-Cancer Early Detection Test","url":"https://stock-news.laohu8.com/highlight/detail?id=2624436565","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624436565?lang=en_us&edition=fundamental","pubTime":"2026-04-02 01:28","pubTimestamp":1775064525,"startTime":"0","endTime":"0","summary":"BRIEF-Superpower Announces Strategic Partnership With GRAIL For Multi-Cancer Early Detection TestApril 1 (Reuters) - Superpower:SUPERPOWER: STRATEGIC PARTNERSHIP WITH GRAIL FOR MULTI-CANCER EARLY DETE","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nFWN40K1BL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624548707","title":"Superpower: Strategic Partnership With Grail for Multi-Cancer Early Detection Test","url":"https://stock-news.laohu8.com/highlight/detail?id=2624548707","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624548707?lang=en_us&edition=fundamental","pubTime":"2026-04-02 01:10","pubTimestamp":1775063436,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nFWN40K1BL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624548083","title":"Superpower partners with Grail to offer Galleri cancer blood test to members","url":"https://stock-news.laohu8.com/highlight/detail?id=2624548083","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624548083?lang=en_us&edition=fundamental","pubTime":"2026-04-02 01:10","pubTimestamp":1775063428,"startTime":"0","endTime":"0","summary":"Grail entered strategic partnership with Superpower to expand access to Galleri multi-cancer early detection blood test through Superpower platform.Superpower members will be able to add Galleri, which screens for cancer signals linked to more than 50 cancer types.PATHFINDER 2 study data showed adding Galleri to standard screenings increased cancer detection more than seven-fold.Offering targets adults at elevated cancer risk, including those aged 50 or older.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL8VgBWr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623442643","title":"Grail Is Maintained at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2623442643","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623442643?lang=en_us&edition=fundamental","pubTime":"2026-03-30 23:35","pubTimestamp":1774884900,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GRAL/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 30, 2026 11:35 ET (15:35 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623312097","title":"Grail price target lowered to $75 from $130 at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2623312097","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623312097?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:54","pubTimestamp":1774871676,"startTime":"0","endTime":"0","summary":"Guggenheim lowered the firm’s price target on Grail (GRAL) to $75 from $130 and keeps a Buy rating on the shares. The firm adjusted models and fore...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/grail-price-target-lowered-to-75-from-130-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/grail-price-target-lowered-to-75-from-130-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621702682","title":"GRAIL (GRAL) Valuation Check As CEO Transition And New Stock Shelf Shape Market Sentiment","url":"https://stock-news.laohu8.com/highlight/detail?id=2621702682","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621702682?lang=en_us&edition=fundamental","pubTime":"2026-03-23 21:07","pubTimestamp":1774271221,"startTime":"0","endTime":"0","summary":"GRAIL (GRAL) is back in focus after announcing that CEO Bob Ragusa will retire in June 2026. President Josh Ofman will take over as CEO and Board member, and a new common stock shelf registration was filed.\nSee our latest analysis for GRAIL.\nThe leadership transition and new stock shelf arrive after a sharp 48.75% 90 day share price decline and a 47.29% negative year to date share price return. However, the 1 year total shareholder return of 45.78% indicates that longer term momentum has...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gral/grail/news/grail-gral-valuation-check-as-ceo-transition-and-new-stock-s","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gral/grail/news/grail-gral-valuation-check-as-ceo-transition-and-new-stock-s","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["GRAL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620023163","title":"BUZZ-Grail rises after TD Cowen upgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=2620023163","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620023163?lang=en_us&edition=fundamental","pubTime":"2026-03-18 17:51","pubTimestamp":1773827497,"startTime":"0","endTime":"0","summary":"BUZZ-Grail rises after TD Cowen upgrade** Shares of diagnostics firm Grail GRAL.O rise 4.2% to $49.36 premarket** Brokerage TD Cowen upgrades GRAIL to “buy” from “hold”, but cuts its price target to $65 from $114** TD Cowen says the recent sell-off after the NHS Galleri trial miss has created an attractive entry point, despite the study missing its main goal** Brokerage says its expert checks remain positive on GRAIL’s blood test that aims to detect multiple cancers early, with a meaningful drop in late-stage cancers** TD Cowen estimates a roughly 75% chance of U.S. approval for the test and around a 50% chance of Medicare coverage** GRAIL shares had fallen about 60% since mid-February before the upgrade, brokerage says ** Shares rose nearly four fold in 2025  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nL4N4060QL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620623163","title":"Grail Shares up 3.7% Premarket After TD Cowen Raises to Buy From Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2620623163","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620623163?lang=en_us&edition=fundamental","pubTime":"2026-03-18 17:50","pubTimestamp":1773827406,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nL4N4060QZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620265231","title":"Analysts’ Top Healthcare Picks: GRAIL Inc (GRAL), Bicycle Therapeutics (BCYC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620265231","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620265231?lang=en_us&edition=fundamental","pubTime":"2026-03-18 17:50","pubTimestamp":1773827405,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on GRAIL Inc (GRAL – Research Report) and Bicycle Thera...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-grail-inc-gral-bicycle-therapeutics-bcyc-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-grail-inc-gral-bicycle-therapeutics-bcyc-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GRAL","XBI","BK4581","HCSG","BCYC","LU0029874061.USD","BK4588","LU0128526141.USD","BK4137","BK4585","LABU","XLV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620392632","title":"Grail Inc : TD Cowen Raises to Buy From Hold; Cuts Target Price to $65 From $114","url":"https://stock-news.laohu8.com/highlight/detail?id=2620392632","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620392632?lang=en_us&edition=fundamental","pubTime":"2026-03-18 17:37","pubTimestamp":1773826667,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nFWN4060N0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620414159","title":"Does GRAIL (GRAL) Elevating Josh Ofman to CEO Reframe Its Management Quality Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2620414159","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620414159?lang=en_us&edition=fundamental","pubTime":"2026-03-17 09:23","pubTimestamp":1773710603,"startTime":"0","endTime":"0","summary":"In March 2026, GRAIL, Inc. announced that CEO Bob Ragusa will retire on June 1, 2026, with President Josh Ofman, MD, MSHS, set to become CEO and join the Board, while Ragusa remains as a senior advisor through March 2027.\nThis leadership transition places a long-time internal executive with deep clinical and health policy experience at the center of GRAIL’s next phase of development.\nNext, we’ll examine how Ofman’s planned move from president to CEO could reshape GRAIL’s investment narrative...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gral/grail/news/does-grail-gral-elevating-josh-ofman-to-ceo-reframe-its-mana","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gral/grail/news/does-grail-gral-elevating-josh-ofman-to-ceo-reframe-its-mana","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619194509","title":"Guggenheim Sticks to Their Buy Rating for GRAIL Inc (GRAL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2619194509","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619194509?lang=en_us&edition=fundamental","pubTime":"2026-03-13 19:58","pubTimestamp":1773403094,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Subbu Nambi from Guggenheim maintained a Buy rating on GRAIL Inc, with a price target of $130.00. The company’s sha...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/guggenheim-sticks-to-their-buy-rating-for-grail-inc-gral-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/guggenheim-sticks-to-their-buy-rating-for-grail-inc-gral-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619547194","title":"Canaccord Genuity Reaffirms Their Buy Rating on GRAIL Inc (GRAL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2619547194","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619547194?lang=en_us&edition=fundamental","pubTime":"2026-03-13 19:57","pubTimestamp":1773403050,"startTime":"0","endTime":"0","summary":"In a report released today, Kyle Mikson CFA from Canaccord Genuity reiterated a Buy rating on GRAIL Inc, with a price target of $80.00. Mikson CFA ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-reaffirms-their-buy-rating-on-grail-inc-gral-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-reaffirms-their-buy-rating-on-grail-inc-gral-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619155765","title":"Grail CEO Bob Ragusa Plans Retirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2619155765","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619155765?lang=en_us&edition=fundamental","pubTime":"2026-03-13 05:09","pubTimestamp":1773349797,"startTime":"0","endTime":"0","summary":"Grail  said late Thursday that Bob Ragusa will retire as chief executive officer, starting June 1.Grail president Josh Ofman will succeed Ragusa, the company said. Ofman was also appointed to the company's board of directors, effective immediately, according to a statement.Ragusa will remain on the board until June 1 and will serve in an advisory role through March 2027, the company said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GRAL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618213206","title":"Levi & Korsinsky probes Grail over 50% stock drop after NHS Galleri trial miss","url":"https://stock-news.laohu8.com/highlight/detail?id=2618213206","media":"Reuters","labels":["policyRegulatory","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618213206?lang=en_us&edition=fundamental","pubTime":"2026-03-12 21:04","pubTimestamp":1773320643,"startTime":"0","endTime":"0","summary":"Levi & Korsinsky said it is investigating potential claims involving Grail after the company disclosed that its NHS Galleri randomized trial failed to meet its primary endpoint, and the stock fell about 50%. The firm cited comments from CEO Robert Ragusa on a Q3 2025 earnings call that Grail expected its cash runway to extend into 2030. It also cited CFO Aaron Freidin’s statement on the same call that 2025 cash burn would be no more than USD 290 million. Levi & Korsinsky is examining whether the company’s forward guidance omitted known risks tied to the NHS trial outcome. Shareholders are directed to click here to discuss your legal rights and to submit their information now.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nNDL6J4ktk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","SG9999014013.SGD","BK4112","BK4139","IE00BKPKM429.USD","LU2210149790.SGD","IE00B64PRP62.GBP","BK4588","SG9999014005.SGD","NDAQ","SG9999014021.USD","SG9999014039.USD","IE00BGHQF748.EUR","GRAL","LU0314104364.USD","LU2210150020.SGD","BK4585","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616666963","title":"Grail Grants 19,500 RSUs to 20 New Hires Under Nasdaq Inducement Rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2616666963","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616666963?lang=en_us&edition=fundamental","pubTime":"2026-03-03 05:01","pubTimestamp":1772485273,"startTime":"0","endTime":"0","summary":"Grail Inc. granted restricted stock units covering a total of 19,500 shares to 20 recently hired non-executive employees under its Inducement Equity Incentive Plan. The awards vest over about four years, with 25% vesting on Feb. 28, 2027 and the remainder vesting on each subsequent one-year anniversary, subject to continued employment through each vesting date.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nNDL5v7nYR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616236659","title":"Grail Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2616236659","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616236659?lang=en_us&edition=fundamental","pubTime":"2026-03-03 05:01","pubTimestamp":1772485260,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nTUA9BZYXR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616807455","title":"Levi & Korsinsky Probes Grail Inc. for Possible Securities Fraud","url":"https://stock-news.laohu8.com/highlight/detail?id=2616807455","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616807455?lang=en_us&edition=fundamental","pubTime":"2026-03-02 13:55","pubTimestamp":1772430943,"startTime":"0","endTime":"0","summary":"Levi & Korsinsky has opened an investigation into Grail Inc. over possible federal securities-law violations, focusing on prior statements about the company’s 2025 cash-burn guidance and projected cash runway into 2030 tied to planned clinical and regulatory milestones. The firm is seeking to hear from investors who incurred losses in Grail securities.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nNDLc2tr7w:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614074924","title":"Grail's Stock Dropped 50% on Friday. Investors Still Have High Hopes for the Biotech. -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2614074924","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614074924?lang=en_us&edition=fundamental","pubTime":"2026-02-27 06:00","pubTimestamp":1772143200,"startTime":"0","endTime":"0","summary":"Grail's highflying stock got cut in half last Friday.The diagnostics company's stock climbed fivefold last year, in part on expectations for a U.K. national study of Grail's blood test that detects dozens of cancers before they are symptomatic. Annual screenings of 140,000 older Brits was hoped to reduce the number of late-stage cancers appearing in the group, after three years.It didn't, and that news last week took Grail shares down from $101 to $50, in a day.After five days of elevated turnover, by Thursday investors seem to have finished their rethinking on the stock. Trading volume returned to an average level and the shares ended the day almost 12% higher, at $58.10.Grail and its fans had hoped the study by Britain's National Health Service would show that detecting cancers early, when they s treatable, would leave fewer late-stage cancers  in a population -- saving jobs, lives and medical expenses. Grail thinks there were fewer Stage IV cancers, but the Stage III cases didn't dr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999002224.SGD","IE0002141913.USD","IE00B4R5TH58.HKD","SGXZ41872573.SGD","BK4139","LU1989763690.USD","LU0170899867.USD","LU1721429402.USD","SG9999004303.SGD","BK4585","LU0122379950.USD","BK4196","LU0058720904.USD","LU0868494617.USD","LU1989763427.SGD","LU2324357040.USD","BK4581","BK4504","GH","IE00BJT1NW94.SGD","LU1691799644.USD","LU2468319806.SGD","LU1023059063.AUD","LU2237957902.USD","LU0266013472.USD","IE00BFTCPJ56.SGD","LU2133065610.SGD","LU1061106388.HKD","LU2211815571.USD","ABT","IE00BJJMRZ35.SGD","SG9999002232.USD","LU1914381329.SGD","IE00B2B36J28.USD","LU0289739699.SGD","BK4551","BK4592","LU0882574055.USD","BK4566","LU1721429741.USD","BK4535","IE0009355771.USD","BK4082","BK4588","ISBC","LABU","BK4568","SGXZ23171101.USD","GRAL","LU2237957811.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614548740","title":"GRAIL to Present at TD Cowen 46th Annual Health Care Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2614548740","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614548740?lang=en_us&edition=fundamental","pubTime":"2026-02-25 05:02","pubTimestamp":1771966976,"startTime":"0","endTime":"0","summary":"GRAIL to Present at TD Cowen 46th Annual Health Care Conference               Grail Inc. said its management will present at the TD Cowen 46th Annual Health Care Conference in Boston on March 3 at 10:","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDL1mpTwt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL","BK4139"],"isVideo":false,"video":null,"gpt_icon":1}],"profile":{"websiteUrl":"http://grail.com;investors.grail.com","stockEarnings":[{"period":"1week","weight":0.0543},{"period":"1month","weight":0.0423},{"period":"3month","weight":-0.3812},{"period":"6month","weight":-0.161},{"period":"1year","weight":1.1037},{"period":"ytd","weight":-0.3575}],"compareEarnings":[{"period":"1week","weight":0.0166},{"period":"1month","weight":-0.036},{"period":"3month","weight":-0.04},{"period":"6month","weight":-0.02},{"period":"1year","weight":0.1617},{"period":"ytd","weight":-0.0383}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"exchange":"NASDAQ","name":"GRAIL, Inc.","nameEN":"GRAIL, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"GRAIL, Inc.(GRAL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest GRAIL, Inc.(GRAL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"GRAIL, Inc.,GRAL,GRAIL, Inc.股票,GRAIL, Inc.股票老虎,GRAIL, Inc.股票老虎国际,GRAIL, Inc.行情,GRAIL, Inc.股票行情,GRAIL, Inc.股价,GRAIL, Inc.股市,GRAIL, Inc.股票价格,GRAIL, Inc.股票交易,GRAIL, Inc.股票购买,GRAIL, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"GRAIL, Inc.(GRAL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest GRAIL, Inc.(GRAL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}